HomeInsightsPE

Aurobindo Pharma Ltd PE Ratio

Aurobindo Pharma Ltd PE Ratio

stocks purchased

₹ 2.3 Cr

Volume transacted

stocks purchased

15.4 K

stocks traded

Last Updated time: 09 Oct 15:30 PM

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

PE

24.7

Last updated: 09 Oct 15:30 PM

Key Highlights

  • The P/E Ratio of Aurobindo Pharma Ltd is 24.7 as of 09 Oct 15:30 PM.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 19.5 on March 2019 to 20.1 on March 2024 . This represents a CAGR of 0.51% over 6 years. .
  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1511 as of 09 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 21.8. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Aurobindo Pharma Ltd

No data available

Company Fundamentals for Aurobindo Pharma Ltd

No data available

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

PRICE

1511.1

20.85 (1.40%)

stock direction

Last updated: 09 Oct 15:30

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
09 Oct 20241511.1
08 Oct 20241490.25
07 Oct 20241466.65
04 Oct 20241466.35
03 Oct 20241457.8
01 Oct 20241438.55
30 Sep 20241460.9
27 Sep 20241509.75
26 Sep 20241515.45
25 Sep 20241527.95

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Aurobindo Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Aurobindo Pharma Ltd2488,541
Sun Pharmaceuticals Industries Ltd434,63,360
Divis Laboratories Ltd941,58,943
Cipla Ltd301,35,756
Torrent Pharmaceuticals Ltd721,20,439
Dr Reddys Laboratories Ltd201,11,289

Key Valuation Metric of Aurobindo Pharma Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Dividend Payout of Aurobindo Pharma Ltd

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma Ltd spurts 1.19%, up for fifth straight session

Aurobindo Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs...

Read more

09 Oct 202413:00

News

Aurobindo Pharma's step down subsidiary to divest its entire stake in a South African JV

Aurogen South Africa, (Aurogen) a wholly owned step-down subsidiary of Aurobindo Pharma in...

Read more

05 Oct 202410:19

News

Aurobindo Pharma's step down subsidiary to divest its entire stake in JV 'Novagen'

Aurogen South Africa (Aurogen), a wholly owned step-down subsidiary of Aurobindo Pharma in...

Read more

05 Oct 202410:21

News

Auro Pharma gets USFDA nod for urinary tract infections drug.

The approved drug is bioequivalent and therapeutically equivalent to the reference listed ...

Read more

03 Oct 202414:58

News

Aurobindo Pharma receives USFDA approval for Cephalexin Tablets

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA...

Read more

01 Oct 202416:30

News

USFDA conducts inspection of Apitoria Pharma's unit II

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) in...

Read more

30 Sep 202414:32

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Aurobindo Pharma Ltd

What is the current PE Ratio of Aurobindo Pharma Ltd?

The Current PE Ratio of Aurobindo Pharma Ltd is 24.68 as on 9 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 9 Oct 2024.

What was the PE Ratio of Aurobindo Pharma Ltd last year?

The PE Ratio of Aurobindo Pharma Ltd was 15.74 last year, now the PE ratio is 24.68, showing a year-on-year growth of 56.8%.

What does the PE Ratio of Aurobindo Pharma Ltd indicate about its stock?

The PE Ratio of Aurobindo Pharma Ltd is 24.68. This ratio indicates that investors are willing to pay 24.68 times the earnings per share for each share of Aurobindo Pharma Ltd.

What is the PE Ratio Growth of Aurobindo Pharma Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Aurobindo Pharma Ltd grew by 56.8% whereas, the EPS ratio grew by 1.2.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*